Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | August 20, 2026 | August 21, 2026 |
| Provention Bio, Inc.PRVB · Entity 12101 | Director | May 17, 2022 | May 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,066 |
Ending reported balance
After 2026-08-20 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2026-08-20 · Exercise / conversion · Acquired 1,165 · Balance 11,231 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 2 · 2026-08-20 · Sale · Disposed 1,165 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F2: Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 3 · 2026-08-20 · Exercise / conversion · Acquired 1,816 · Balance 11,882 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 4 · 2026-08-20 · Sale · Disposed 1,816 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F3: Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 5 · 2026-08-20 · Exercise / conversion · Acquired 1,658 · Balance 11,724 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 6 · 2026-08-20 · Sale · Disposed 1,658 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F4: Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 7 · 2026-08-20 · Exercise / conversion · Acquired 26 · Balance 10,092 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 8 · 2026-08-20 · Sale · Disposed 26 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 9 · 2026-08-20 · Exercise / conversion · Acquired 335 · Balance 10,401 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 10 · 2026-08-20 · Sale · Disposed 335 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.45 · Expires 2031-05-12 | Direct | 0 |
Reported balance
After 2026-08-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-20 · Exercise / conversion · Disposed 4,665 · Balance 0 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F5: 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.35 · Expires 2032-05-05 | Direct | 11,395 |
Reported balance
After 2026-08-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-20 · Exercise / conversion · Disposed 335 · Balance 11,395 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F6: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.
F2: Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3: Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F4: Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F5: 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested.
F6: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.
Provention Bio, Inc.
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2032-05-17 | Direct | 33,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 33,000 · Balance 33,000 F2: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 17, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 17, 2023.
F2: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2020 Filed Apr 14, 2020 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GiftEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001493152-20-006374 · ownership.xml · derivative · entry 5 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2029-06-24 F5 · kind: On February 27, 2020, the reporting person contributed options to purchase up to 24,000 shares of Common Stock to the Bluestone Family Trust as a gift. The option was granted on June 24, 2019, pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F6 · derivative.exercise_date: The option fully vests on May 28, 2020. Read SEC document |
| February 27, 2020 Filed Apr 14, 2020 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GiftEmployee Stock Option (right to buy) · Derivative | 128,981 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001493152-20-006374 · ownership.xml · derivative · entry 3 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bluestone Family Trust Disclosed balance after: 0 Underlying: Common Stock · 128,981 shares Expires 2029-03-27 F3 · kind: On February 27, 2020, the reporting person contributed options to purchase up to 128,981 shares of Common Stock to the Bluestone Family Trust as a gift. The option was granted on March 27, 2019, pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F4 · derivative.exercise_date: The option vests in eight equal semi-annual installments commencing on September 27, 2019 and will become fully vested on March 27, 2023. F2 · ownership.nature: The reporting person, together with his spouse are trustees and the reporting person, his spouse and children are the beneficiaries of the Bluestone Family Trust. Read SEC document |
| February 27, 2020 Filed Apr 14, 2020 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GiftEmployee Stock Option (right to buy) · Derivative | 128,981 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001493152-20-006374 · ownership.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128,981 shares Expires 2029-03-27 F3 · kind: On February 27, 2020, the reporting person contributed options to purchase up to 128,981 shares of Common Stock to the Bluestone Family Trust as a gift. The option was granted on March 27, 2019, pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F4 · derivative.exercise_date: The option vests in eight equal semi-annual installments commencing on September 27, 2019 and will become fully vested on March 27, 2023. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 16:07 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 24,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001493152-19-009679 · ownership.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock, par value $0.0001 · 24,000 shares Expires 2029-06-24 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The option fully vests on May 28, 2020. Read SEC document |
| June 17, 2019 Filed Jun 17, 2019 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | SaleCommon Stock | 7,300 | $11.93 | $87,089.00 |
DisclosureSEC source: 0001493152-19-009337 · ownership.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,325 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.15, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 17:15 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 128,981 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001493152-19-004128 · ownership.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,981 Underlying: Common Stock, par value $0.0001 · 128,981 shares Expires 2029-03-27 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The option vests in eight equal semi-annual installments commencing on September 27, 2019 and will become fully vested on March 27, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.